Related Experiment Video
Updated: Jun 16, 2025

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
Azvudine Suppresses Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma by Targeting the Notch-HEY
Yao Meng1,2, Peiyi Sun1,2, Yixin Ren3
1Beijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development/Laboratory of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Abstract:
Azvudine (FNC) is a novel cytidine analogue that is widely used in the treatment of infectious diseases such as AIDS and COVID-19. Previous studies have demonstrated its anticancer activity in various cancer cell lines, including non-Hodgkin's lymphomas and lung adenocarcinoma cell lines. However, its effects on hepatocellular carcinoma (HCC) and the underlying mechanisms remain unclear. This study aimed to investigate the anti-epithelial-mesenchymal transition (anti-EMT) activity of FNC and evaluate its potential application in HCC treatment. We found that FNC significantly inhibits the migration of the liver cancer cell line Huh7 by downregulating key EMT markers, such as matrix metalloproteinases (MMPs) and N-cadherin, at both the transcriptional and protein expression levels. Notably, we found that FNC inhibits HEY proteins, particularly HEY1, a transcriptional regulator of the Notch signalling pathway that is overexpressed in approximately 50% of HCC patients. To identify the primary target of FNC, microscale thermophoresis (MST) and molecular dynamics (MD) simulations were performed, revealing that FNC directly binds to Jagged1. This study provides valuable insights into the therapeutic potential of FNC in HCC treatment and elucidates its underlying mechanisms.
Insights
Azvudine (FNC) inhibits liver cancer cell migration by targeting Jagged1 and downregulating epithelial-mesenchymal transition (EMT) markers. This antiviral drug shows promise for hepatocellular carcinoma (HCC) treatment by interfering with key cancer pathways.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Azvudine (FNC), an antiviral cytidine analogue, has shown anticancer effects in various cell lines.
- Its efficacy and mechanisms in hepatocellular carcinoma (HCC) remain largely unexplored.
- Epithelial-mesenchymal transition (EMT) is a critical process in cancer progression and metastasis.
Purpose of the Study:
- To investigate the anti-EMT activity of Azvudine (FNC) in hepatocellular carcinoma (HCC).
- To elucidate the molecular mechanisms underlying FNC's effects on liver cancer cells.
- To evaluate FNC's potential as a therapeutic agent for HCC.
Main Methods:
- Utilized the Huh7 liver cancer cell line to assess FNC's impact on cell migration.
- Analyzed key EMT markers (MMPs, E-cadherin) at transcriptional and protein levels.
- Employed microscale thermophoresis (MST) and molecular dynamics (MD) simulations to identify FNC's molecular target.
Main Results:
- FNC significantly inhibited Huh7 cell migration.
- FNC downregulated crucial EMT markers, including MMPs and E-cadherin.
- FNC was found to directly bind to Jagged1, a key component of the Notch signaling pathway implicated in HCC.
Conclusions:
- Azvudine (FNC) exhibits anti-EMT activity and inhibits hepatocellular carcinoma (HCC) cell migration.
- FNC targets Jagged1, suggesting a novel therapeutic mechanism for HCC.
- FNC demonstrates significant potential for HCC treatment, warranting further clinical investigation.
Related Concept Videos
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Regulation of Angiogenesis and Blood Supply
Abnormal Proliferation
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways

